SAN ANTONIO, TX and ANN ARBOR, MI, January 8, 2020 – StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) are pleased to announce that StemBioSys has acquired a majority stake in Cartox. StemBioSys will acquire all remaining equity of Cartox subject to the achievement of certain milestones. [Read more…]
KATAOKA Introduces CPD-017 Cell Processor for High-Speed Biomanufacturing
Unwanted cell removal and cell sorting can be easily performed at high-speed.
TORRANCE, Calif. – Kataoka-SS America, a US subsidiary of Kataoka Corporation Kyoto Japan, has launched its sales of their Cell Processor CPD-017 to the U.S. market. Kataoka`s Cell Processor uses laser technology to scan, identify, and irradiate spontaneously differentiated cells without dissociation or applied stress to the cells.
With the CPD-017, the process time of purifying induced pluripotent stem cell (iPSC) is significantly reduced and the adherent cell colonies can maintain a stress-free healthy condition. [Read more…]
CBR Announces New Pediatric Genetic Screening Test in Collaboration with Sema4
Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.
LOS ANGELES, Nov. 15, 2019 — CBR, the global leader in newborn stem cell banking, has announced a new genetic service developed over the past couple of years as part of a strategic alliance with Sema4. As a patient-centered health intelligence company and leading innovator within the genomic testing industry, Sema4 collaborated with CBR to launch ReadyGen™, a highly accurate genetic screening test that analyzes a child’s DNA for more than 200 conditions that can affect children before the age of 10. [Read more…]
Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells)
-
Principal investigator Dr. Jaime Guevara Aguirre, world-renowned expert on growth hormone to conduct the trial of Altsulin® (Microencapsulated Sertoli Cells) in Laron Syndrome Patients
-
Laron Syndrome (aka Laron-type dwarfism) is a rare pediatric orphan disease eligible for the FDA “Golden Ticket”
-
Phase IIa proof-of-concept trial paves the way to commercial development of Sertoli Cells for the treatment of Type I Diabetes
Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer’s, Stem cell pioneer Bill Skarnes joins advisory board
REDWOOD CITY, Calif., Oct. 22, 2019 — Synthego, the leading genome engineering company, announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale. [Read more…]
- « Previous Page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- …
- 116
- Next Page »